IGF-1R and mTOR Blockade: Novel Resistance Mechanisms and Synergistic Drug Combinations for Ewing Sarcoma.

@article{LamhamediCherradi2016IGF1RAM,
  title={IGF-1R and mTOR Blockade: Novel Resistance Mechanisms and Synergistic Drug Combinations for Ewing Sarcoma.},
  author={Salah-Eddine Lamhamedi-Cherradi and Brian A. Menegaz and Vandhana Ramamoorthy and Deeksha Vishwamitra and Ying Wang and Rebecca L Maywald and Adriana S Buford and Izabela Fokt and Stanislaw Skora and Jing Wang and Aung S. Naing and Alexander J Lazar and Eric M. Rohren and Najat C. Daw and Vivek Subbiah and Robert S Benjamin and Ravin Ratan and Waldemar Priebe and Antonios G Mikos and Hesham M. Amin and Joseph A. Ludwig},
  journal={Journal of the National Cancer Institute},
  year={2016},
  volume={108 12}
}
BACKGROUND Therapies cotargeting insulin-like growth factor receptor 1 (IGF-1R) and mammalian target of rapamycin (mTOR) have demonstrated remarkable, albeit short-lived, clinical responses in a subset of Ewing sarcoma (ES) patients. However, the mechanisms of resistance and applicable strategies for overcoming drug resistance to the IGF-1R/mTOR blockade are still undefined. METHODS To elucidate predominant mechanism(s) of acquired drug resistance while identifying synergistic drug… CONTINUE READING